Details for New Drug Application (NDA): 219918
✉ Email this page to a colleague
NDA 219918 describes RIFAMPIN, which is a drug marketed by Chartwell Molecular, Epic Pharma Llc, Hikma, Lupin Pharms, Novitium Pharma, Avet Lifesciences, Fresenius Kabi Usa, Hikma Pharms, Mylan Labs Ltd, Watson Pharms Teva, and Hikma Intl Pharms, and is included in thirteen NDAs. It is available from thirteen suppliers. Additional details are available on the RIFAMPIN profile page.
The generic ingredient in RIFAMPIN is isoniazid; rifampin. There are five drug master file entries for this compound. Additional details are available on the isoniazid; rifampin profile page.
The generic ingredient in RIFAMPIN is isoniazid; rifampin. There are five drug master file entries for this compound. Additional details are available on the isoniazid; rifampin profile page.
Summary for 219918
| Tradename: | RIFAMPIN |
| Applicant: | Novitium Pharma |
| Ingredient: | rifampin |
| Patents: | 0 |
Suppliers and Packaging for NDA: 219918
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RIFAMPIN | rifampin | CAPSULE;ORAL | 219918 | ANDA | ANI Pharmaceuticals, Inc. | 70954-892 | 70954-892-10 | 30 CAPSULE in 1 BOTTLE (70954-892-10) |
| RIFAMPIN | rifampin | CAPSULE;ORAL | 219918 | ANDA | ANI Pharmaceuticals, Inc. | 70954-892 | 70954-892-20 | 100 CAPSULE in 1 BOTTLE (70954-892-20) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 150MG | ||||
| Approval Date: | Jun 29, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 300MG | ||||
| Approval Date: | Jun 29, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
